Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome.

Lupus·2018
Same author

Feasibility of Patient-Reported Outcomes Measurement Information System (PROMIS®) computerized adaptive tests in systemic lupus erythematosus outpatients.

Lupus·2018
Same author

Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome.

Lupus·2014
Same author

Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies.

Thrombosis and haemostasis·2002
Same author

Update on the management of the pregnant patient with antiphospholipid antibody.

Current rheumatology reports·2001
Same author

Validation of the Sapporo criteria for antiphospholipid syndrome.

Arthritis and rheumatism·2000
Same journal

Risk of Femoral Head Osteonecrosis Following Hip Trauma in Adults With Systemic Lupus Erythematosus.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Microbiome Dysbiosis as a Potential Driver of Inflammatory Mimicry in Pachydermoperiostosis-associated Hypertrophic Osteoarthropathy.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Understanding Gaps in Methotrexate Education in the Adolescent and Young Adult Population.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Prevalence of Attention Deficit Hyperactivity Disorder in Adult Patients With Fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Update: antiphospholipid antibodies.

L R Sammaritano1

  • 1Division of Rheumatology, Hospital for Special Surgery, Cornell University Medical College, New York, New York.

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Antiphospholipid antibodies (aPL) are linked to a syndrome causing blood clots and pregnancy loss. New research shows these antibodies target proteins, not just phospholipids, paving the way for better treatments.

More Related Videos

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 27, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics

Background:

  • Antiphospholipid antibodies (aPL) are associated with a clinical syndrome involving thrombosis and pregnancy complications.
  • The syndrome is characterized by venous/arterial thrombosis, thrombocytopenia, and recurrent fetal loss.
  • Previous understanding suggested aPL targeted phospholipids directly.

Purpose of the Study:

  • To update the understanding of antiphospholipid antibody (aPL) targets.
  • To explore the immunological basis of antiphospholipid antibody syndrome (APS).
  • To identify potential new therapeutic targets for APS.

Main Methods:

  • Review of current literature on aPL immunology and clinical manifestations.
  • Analysis of recent findings on the antigenic targets of aPL.
  • Synthesis of information on established and emerging therapies for APS.

Main Results:

  • Antiphospholipid antibodies (aPL) recognize phospholipid-binding proteins (e.g., beta2-glycoprotein I), not solely phospholipids.
  • This recognition of protein epitopes may explain the varied clinical presentations of antiphospholipid antibody syndrome (APS).
  • Current treatments include anticoagulation for thrombosis and aspirin/heparin for pregnancy complications.

Conclusions:

  • Antiphospholipid antibodies (aPL) target specific phospholipid-binding proteins, refining the understanding of antiphospholipid antibody syndrome (APS) pathogenesis.
  • Identification of these protein targets offers promise for developing novel therapeutic strategies.
  • Continued research into aPL immunology is crucial for improving patient outcomes.